

February 12, 2023

**BSE Limited**

P. J. Towers,  
Dalal Street,  
Mumbai- 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1,  
G Block Bandra-Kurla Complex,  
Bandra (E) Mumbai- 400 051

**Scrip Code-540025**

**Trading Symbol-ADVENZYMES**

Dear Sir,

**Sub: Newspaper publication of Extract of Un-audited Consolidated Financial Results for the quarter ended December 31, 2022.**

**Ref: ISIN: INE837H01020**

Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the newspaper publication of 'Extract of Un-audited Consolidated Financial Results for the quarter ended December 31, 2022' published in The Free Press Journal and Navshakti on February 12, 2023.

Thanking you,


Yours faithfully,

**For Advanced Enzyme Technologies Limited**

**Sanjay Basantani**

**Company Secretary and Head – Legal**

Encl.: As above



# Advanced Enzyme Technologies Limited

CIN : L24200MH1989PLC051018

**Regd. Office and Corporate Office:** Sun Magnetica, 5th Floor, LIC Service Road, Louiswadi, Thane - 400604, Maharashtra, India. **Tel No :** 91-22-41703220 **Fax No:** +91-22-25835159  
**Website:** www.advancedenzymes.com, **Email Id :** sanjay@advancedenzymes.com

## EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(₹ in million except the Earnings per share)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	Dec 31, 2022 (Unaudited)	Sept 30, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	Dec 31, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	Mar 31, 2022 (Audited)
Total income from operations	1,421.12	1,386.93	1,335.58	4,019.27	3,976.49	5,293.83
Net Profit / (Loss) for the period (before tax, exceptional and/ or extraordinary items)	404.53	341.37	411.23	982.86	1,371.10	1,710.58
Net Profit / (Loss) for the period before tax (after exceptional and/ or extraordinary items)	404.53	341.37	411.23	982.86	1,371.10	1,710.58
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	279.10	262.61	285.55	717.51	985.44	1,237.99
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	430.36	457.30	280.70	1,294.67	1,031.89	1,403.19
Equity Share Capital	223.64	223.64	223.58	223.64	223.58	223.60
Reserves excluding Revaluation Reserve as per the last audited Balance Sheet						10,662.33
Earnings Per Share of ₹ 2 each (not annualised) (for continuing and discontinued operations)						
Basic	2.63	2.34	2.46	6.57	8.51	10.70
Diluted	2.63	2.34	2.45	6.57	8.50	10.68

### Notes:

- (i) The above is an extract of the detailed format of consolidated unaudited financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A.), Advanced Enzymes (Malaysia) Sdn. Bhd. (Malaysia), Advanced Enzymes Europe B.V. (Netherlands) and Evoxx Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".
- (ii) The above is an extract of the detailed format of consolidated unaudited financial results for the quarter and nine months ended 31 December 2022 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of quarterly results (standalone and consolidated) for the quarter and nine months ended 31 December 2022 are available on the Stock Exchange's website: www.bseindia.com and www.nseindia.com and on Company's website: www.advancedenzymes.com.
- (iii) On 3 January 2023, the Company has acquired additional stake of 4.83% in its subsidiary JC Biotech Private Limited for a consideration of Rs 68.00 million. Post this additional acquisition the Company holds 89.83% stake in JC Biotech Private Limited.
- (iv) On 3 January 2023, the Company completed the acquisition of 50% of the paid up equity share capital in Saiganesh Enzytech Solutions Private Limited ("SESPL") for a total consideration of Rs 59.97 million. SESPL is primarily engaged into extracting Latex from papaya, purifying and providing finish papain enzyme in liquid form (agriculture extraction of Papain enzyme).
- (v) The above financial results of the Company were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 11 February 2023.
- (vi) The key standalone financial information are as under:

(₹ in million)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	Dec 31, 2022 (Unaudited)	Sept 30, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	Dec 31, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	Mar 31, 2022 (Audited)
Total income from operations	796.82	771.77	643.87	2,289.69	2,020.50	2,727.98
Profit before tax	223.11	184.13	117.75	510.00	541.06	720.72
Profit after tax	166.36	136.16	87.70	380.30	401.59	545.11

By Order of the Board  
For Advanced Enzyme Technologies Limited

M. M. Kabra  
Wholesale Director  
DIN : 00148294





# Advanced Enzyme Technologies Limited

CIN : L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, LIC Service Road,  
Louiswadi, Thane - 400604, Maharashtra, India. Tel No : 91-22-41703220 Fax No: +91-22-25835159  
Website: www.advancedenzymes.com, Email Id : sanjay@advancedenzymes.com

## EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(₹ in million except the Earnings per share)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	Dec 31, 2022 (Unaudited)	Sept 30, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	Dec 31, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	Mar 31, 2022 (Audited)
Total income from operations	1,421.12	1,386.93	1,335.58	4,019.27	3,976.49	5,293.83
Net Profit / (Loss) for the period (before tax, exceptional and/ or extraordinary items)	404.53	341.37	411.23	982.86	1,371.10	1,710.58
Net Profit / (Loss) for the period before tax (after exceptional and/ or extraordinary items)	404.53	341.37	411.23	982.86	1,371.10	1,710.58
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	279.10	262.61	285.55	717.51	985.44	1,237.99
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	430.36	457.30	280.70	1,294.67	1,031.89	1,403.19
Equity Share Capital	223.64	223.64	223.58	223.64	223.58	223.60
Reserves excluding Revaluation Reserve as per the last audited Balance Sheet						10,662.33
Earnings Per Share of ₹ 2 each (not annualised) (for continuing and discontinued operations)						
Basic	2.63	2.34	2.46	6.57	8.51	10.70
Diluted	2.63	2.34	2.45	6.57	8.50	10.68

### Notes:

- The above is an extract of the detailed format of consolidated unaudited financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A.), Advanced Enzymes (Malaysia) Sdn. Bhd. (Malaysia), Advanced Enzymes Europe B.V. (Netherlands) and Evovx Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".
- The above is an extract of the detailed format of consolidated unaudited financial results for the quarter and nine months ended 31 December 2022 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of quarterly results (standalone and consolidated) for the quarter and nine months ended 31 December 2022 are available on the Stock Exchange's website: www.bseindia.com and www.nseindia.com and on Company's website: www.advancedenzymes.com.
- On 3 January 2023, the Company has acquired additional stake of 4.83% in its subsidiary, JC Biotech Private Limited for a consideration of Rs. 68.00 million. Post this additional acquisition the Company holds 89.83% stake in JC Biotech Private Limited.
- On 3 January 2023, the Company completed the acquisition of 50% of the paid up equity share capital in Saiganesh Enzytech Solutions Private Limited ('SESPL') for a total consideration of Rs 59.97 million. SESPL is primarily engaged into extracting Latex from papaya, purifying and providing finish papain enzyme in liquid form (agriculture extraction of Papain enzyme).
- The above financial results of the Company were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 11 February 2023.
- The key standalone financial information are as under:

(₹ in million)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	Dec 31, 2022 (Unaudited)	Sept 30, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	Dec 31, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	Mar 31, 2022 (Audited)
Total income from operations	796.82	771.77	643.87	2,289.69	2,020.50	2,727.98
Profit before tax	223.11	184.13	117.75	510.00	541.06	720.72
Profit after tax	166.36	136.16	87.70	380.30	401.59	545.11

By Order of the Board  
For Advanced Enzyme Technologies Limited

Place : Nashik  
Date : 11<sup>th</sup> February, 2023

M. M. Kabra  
Wholetime Director  
DIN : 00148294